Oxford Quantum Circuits raises £38 million Series A to accelerate R&D and expand into APAC
5.7.2022 08:00:00 EEST | Business Wire | Press release
Oxford Quantum Circuits (OQC), Europe’s leading quantum computing company, today announced raising £38 million (US $46.45 million) in the first close of an on-going Series A. The investment is the UK’s largest ever Series A in quantum computing and will accelerate research and development and fuel expansion in Asia-Pacific. The round was co-led by Lansdowne Partners, one of Europe’s leading investment firms, and The University of Tokyo Edge Capital Partners (UTEC), Japan’s largest deeptech VC fund. British Patient Capital and existing investors Oxford Science Enterprises (OSE) and Oxford Investment Consultants (OIC) also participated.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220704005233/en/
Deployment of OQC's 8 qubits processor Lucy by two quantum engineers. (c) Oxford Quantum Circuits
OQC’s patented 3D architecture, the Coaxmon, combines unparalleled scalability with world-class performance. This funding follows the February 2022 launch of OQC’s latest system, Lucy, on Amazon Braket - making it the first European quantum company on AWS. The company’s technology can be used by businesses in financial services, pharma and logistics to increase their competitive edge.
This Series A investment will be used to further scale the company’s quantum systems and its private quantum computing as-a-service offering. It will also consolidate OQC’s position in Europe and accelerate international expansion in Asia-Pacific, including the Japanese market - a hotspot for financial services eager to realise the advantages of quantum computing.
Quantum computing has the potential to shape our future and improve people’s lives and has long been recognised as a matter of strategic national importance. British Patient Capital’s investment in the round is part of its wider ambition to cement the UK’s position as a science and technology superpower.
Lenny Chin, Principal at UTEC, said “Quantum computing promises to be the next frontier of innovation, and OQC, with its state-of-the-art Coaxmon technology, aims to integrate the forefront of modern physics into our everyday lives. UTEC is honoured to be part of OQC’s mission of making quantum technology accessible to all and will support OQC’s expansion into Asia-Pacific through collaborations with academia including the University of Tokyo, and partnerships with Japan’s leading financial and tech corporations.”
Peter Davies, Partner & Head of Developed Markets Strategy at Lansdowne Partners, said “Since launching the UK’s first commercially-available quantum computer, we have continued to be highly impressed with both the technical developments and also the future ambitions of OQC. We are very excited to be investing in this innovative and forward-thinking company.”
Judith Hartley, CEO, British Patient Capital said “The UK has long been at the forefront of global technology developments. Our investment in Oxford Quantum Circuits exemplifies our continued commitment to ensuring the UK stays at the forefront of deeptech innovation. The sphere of quantum computing is a vital link in the chain of technological, scientific, and business advancement, from breakthroughs to better business modelling across the board. We are excited to help fund OQC’s expansion into the Asia-Pacific regions, allowing this new frontier in technology to develop even further through exposure to the global market.”
Ilana Wisby, CEO of OQC, said “This initial close is the UK’s largest ever Series A in quantum computing, demonstrating the confidence our investors have in our ability to lead the global quantum industry. It’s testament to the significant technological and commercial progress we have achieved in recent months, thanks to our world-class team. It is also the first step in our international expansion, bringing quantum to our customers’ fingertips – wherever they are in the world.”
Editors’ Notes
About OQC: OQC is Europe’s leading quantum computing company. We bring quantum to our customers’ fingertips and enable them to make breakthrough discoveries. Our quantum computers are available via private cloud and on Amazon Braket.
About Lansdowne: Lansdowne Partners is a European headquartered investment manager operating a diversified range of actively managed equity strategies.
www.lansdownepartners.com/london
About UTEC: The University of Tokyo Edge Capital Partners, Inc. is the largest venture capital fund focused on science and technology in Japan, and one of the largest deep tech funds in Asia. UTEC has invested in over 140 Japanese and Global startups with a track record of 17 IPOs & 14 M&As.
About BPC: British Patient Capital is the trading name of British Patient Capital Limited, a wholly-owned commercial subsidiary of British Business Bank plc, the UK government’s economic development bank. Launched in June 2018, British Patient Capital has £2.5bn to invest over 10 years in venture and venture growth capital to support high growth potential innovative UK businesses.
www.britishpatientcapital.co.uk
About OSE: Oxford Science Enterprises (OSE) is a Science Business Builder, committed to helping solve the world’s toughest problems for more people, in more places, faster. The company does this by transforming world-leading science into world-changing businesses, partnering the best scientists from the world’s best university with the best business brains.
www.oxfordscienceenterprises.com
About OIC: Oxford Investment Consultants backs extraordinary founders turning scientific research into products addressing the world’s greatest challenges. The OIC team has decades of investment experience, partnering with transformative biotech, healthcare and deeptech companies from Oxford University and other world-leading UK research institutions.
www.oxfordinvestmentconsultants.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220704005233/en/
Contact information
Kaya Cheshire
ThoughtLDR Ltd.
kaya@thoughtldr.com
+44 7464 338017
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AV Access Presents eShare W90: A 4K Wireless Conferencing System for Smarter Hybrid Meetings at ISE 2026 in Barcelona28.1.2026 10:00:00 EET | Press release
AV Access proudly announces its participation in ISE 2026, one of the world’s leading AV and systems integration exhibitions. From February 3-6 at the Fira de Barcelona, Gran Via, the company will showcase its latest solutions designed to improve collaboration, enhance entertainment, and boost workplace productivity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128178621/en/ The eShare W90 wireless presentation and conferencing system makes hybrid meetings more secure, more collaborative, and far easier to manage. At Booth 1F110, AV Access will highlight its flagship innovations, including the eShare W90 wireless conferencing system, the plug-and-play 4KIP200 HDMI over IP solution, and the complete iDock series of KVM docking stations—demonstrating its dedication to versatile, high-performance AV technology. Stream, Charge and Share with a Single USB-C Cable At the heart of the booth is the eShare W90 wireless presentat
SES Extends EGNOS GEO-1 Satellite Service to Power Precise Navigation Across Europe28.1.2026 09:50:00 EET | Press release
SES, a leading space solutions company, and the European Union Agency for the Space Programme (EUSPA) today announced an extension of the European Geostationary Navigation Overlay Service (EGNOS) GEO-1 satellite service agreement through 2030, with an option to extend until 2032, helping maintain high-precision navigation services for aviation and other critical users across Europe. By improving the accuracy and integrity of satellite positioning signals, EGNOS supports aircraft in landing in low-visibility conditions, as well as planning more efficient routes, reducing fuel burn and CO₂ emissions. At the core of the EGNOS service is Europe’s regional Satellite-Based Augmentation System (SBAS) that improves the accuracy and reliability of Global Navigation Satellite System (GNSS) signals, such as GPS. Beyond aviation, EGNOS supports maritime navigation and precision-driven agriculture, contributing to efficient operations and sustainability by reducing fuel consumption and emissions. U
LTTS Secures Strategic Engineering and R&D Agreement from Global Automotive OEM28.1.2026 09:30:00 EET | Press release
L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, announced that it has secured a significant multi-year engagement in its Mobility segment from a leading automotive OEM. The strategic win further strengthens LTTS’ long-standing partnership with the premium automotive manufacturer and underscores its growing role in supporting next-generation mobility engineering. The engagement encompasses advanced software, connectivity and digital engineering services across multiple vehicle technology domains. LTTS will draw on its global engineering expertise, strong domain knowledge and proven delivery frameworks to support the customer’s evolving product and technology roadmap. This win reinforces LTTS’ comprehensive mobility engineering capabilities, spanning embedded systems, digital platforms, verification and validation, cloud integration, cybersecurity, and cross-disciplinary software–mechanical engineering. LTTS’ investments in sta
SFI Health™ EMEA Announces the Launch in Poland of Equazen ® Forte, Marking a New Chapter in Cognitive Support for Young Adults and Adults28.1.2026 09:00:00 EET | Press release
SFI Health™ EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, today is pleased to announce the launch of Equazen® Forte in Poland, a new concentrated omega 3 product formulation to be added to the Equazen® range designed to support the normal cognitive performance for young adults and adults. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127646023/en/ Equazen® Forte: a key milestone in the brand’s long-term development strategy. Equazen® Forte represents a key milestone in the brand’s long-term development strategy. Traditionally recognized as a pediatric brain health expert, Equazen® is now evolving to support consumers across different life stages, addressing changing cognitive demands from adolescence into adulthood. Equazen® Forte builds on more than 25 years of Equazen® heritage and scientific expertise. Like the rest of the Equazen® range, it features the brand’s unique and clinically
Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G pTau 217 CSF Assay for Research Use Only28.1.2026 08:07:00 EET | Press release
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 CSF assay for the fully automated LUMIPULSE® G immunoassay analyzers. This CLEIA (chemiluminescent enzyme immunoassay) assay is available for Research Use Only (RUO) and allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human cerebrospinal fluid (CSF) within just 35 minutes. Alzheimer’s disease (AD) is characterized by the accumulation of neurofibrillary tangles in the brain, composed of hyperphosphorylated tau, and amyloid plaques, consisting of distinct β-amyloid peptides. CSF pTau217 has emerged as an early biomarker for neuropathological changes associated with AD. This new immunoassay further strengthens Fujirebio’s growing portfolio of neurological biomarkers and reinforces the company’s leading position in the advancement of associated research tools and diagnostics. “By adding pTau 217 CSF to our neuro portfol
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom